For years, researchers and clinicians compared tirzepatide and semaglutide only through cross-trial analysis — comparing STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) data from different populations and protocols. SURMOUNT-5 changed that by running the first head-to-head RCT. Here’s what the published data shows. This overview specifically addresses tirzepatide vs semaglutide, and related research is indexed on PubMed.
The Mechanism Difference
Semaglutide is a selective GLP-1 receptor agonist — it binds only to the GLP-1 receptor. Tirzepatide is a dual agonist that activates both the GLP-1 receptor AND the GIP (glucose-dependent insulinotropic polypeptide) receptor with roughly equal potency. This is the pharmacological basis for any claimed difference in outcomes.
GIP is itself an incretin hormone produced in the duodenum. GIP receptors are expressed in adipose tissue, pancreatic beta cells, and the CNS. The hypothesis is that activating both receptor classes simultaneously produces synergistic effects on energy balance that neither compound can achieve alone.
Cross-Trial Comparison (Indirect)
Before head-to-head data existed, researchers compared:
- STEP-1 (semaglutide 2.4mg, n=1961): ~14.9% mean body weight reduction at 68 weeks
- SURMOUNT-1 (tirzepatide 15mg, n=2539): ~20.9% mean body weight reduction at 72 weeks
This indirect comparison favored tirzepatide, but the populations, protocols, and endpoints differed — making direct conclusions scientifically problematic. SURMOUNT-5 was designed to resolve this.
SURMOUNT-5: The Head-to-Head Trial
Published in the New England Journal of Medicine in early 2025. 751 participants with obesity (no diabetes), randomized to tirzepatide (max 15mg) vs semaglutide (max 2.4mg), 72 weeks. Both drugs dosed at maximum approved doses.
Key reported findings:
- Tirzepatide: 20.2% mean body weight reduction
- Semaglutide: 13.7% mean body weight reduction
- Absolute difference: ~6.5 percentage points favoring tirzepatide
- 47% of tirzepatide participants achieved ≥25% body weight reduction vs 19% with semaglutide
The difference was statistically significant (p<0.001). This is the strongest direct evidence supporting tirzepatide’s superiority for body weight outcomes in a non-diabetic obese population at maximum doses.
Important Caveats
- One trial is not proof — replication matters
- Side effect profiles were similar but not identical; GI events were common in both groups
- Long-term cardiovascular outcome data for tirzepatide is still emerging (SURPASS-CVOT ongoing)
- Individual response varies substantially — some participants respond better to one compound than the other
- Cost and access differ significantly between compounds
Tolerability: Was the Efficacy Advantage Offset by More Side Effects?
A natural question given tirzepatide’s larger effect size in SURMOUNT-5: did it come with proportionally worse tolerability? Gastrointestinal side effects (nausea, diarrhea, constipation, vomiting) are the dominant adverse-event category for both drug classes, driven by the same GLP-1 receptor mechanism they share. Published tolerability data from SURMOUNT-5 and the broader trial literature generally describes discontinuation rates due to adverse events as broadly similar between the two drugs at their respective maximum approved doses, rather than tirzepatide showing a substantially worse safety profile despite its larger weight-loss effect — though individual GI symptom incidence rates have varied somewhat by specific symptom across the trial literature. This is a relevant data point for interpreting the efficacy comparison: the additional weight loss with tirzepatide in this trial was not clearly bought at the cost of proportionally worse tolerability.
Where This Comparison Is Headed: Retatrutide
The GIP/GLP-1 dual-agonism story extends further with retatrutide, a triple agonist that adds glucagon receptor activation on top of GLP-1 and GIP agonism — see our dedicated retatrutide overview for detail on its distinct mechanism and trial data. Retatrutide’s Phase 2 trial data has reported even larger weight-reduction percentages than tirzepatide’s pivotal trials, extending the same basic hypothesis tested by SURMOUNT-5 (that engaging additional incretin/glucagon receptor pathways alongside GLP-1 produces additive metabolic benefit) one step further, pending its own completed Phase 3 program and eventual head-to-head data against tirzepatide.
Frequently Asked Questions
Does dual GIP/GLP-1 agonism cause meaningfully more side effects than GLP-1 agonism alone?
Based on SURMOUNT-5 and the broader trial literature, discontinuation rates due to adverse events have generally been broadly comparable between tirzepatide and semaglutide at their approved maximum doses, rather than showing a clearly worse tolerability profile for the dual agonist despite its larger effect size.
Is retatrutide expected to outperform tirzepatide the way tirzepatide outperformed semaglutide?
Retatrutide’s Phase 2 data has shown larger reported weight-reduction percentages, but a completed Phase 3 program and a direct head-to-head trial against tirzepatide (analogous to SURMOUNT-5) would be needed to confirm this with the same rigor applied to the tirzepatide-vs-semaglutide comparison.
Does a larger average weight-loss percentage mean a drug is better for every patient?
Not necessarily — average trial results describe population-level outcomes; individual response, tolerability, cost, and access all factor into which specific medication is appropriate for a given patient, a decision made with a prescribing physician rather than based on trial averages alone.
Research Context
This comparison is academically significant for understanding incretin biology — specifically whether activating GIP receptors alongside GLP-1 receptors provides additive or synergistic metabolic effects. The SURMOUNT-5 data suggests it does, at least for body weight outcomes, providing support for the dual agonism hypothesis.
Educational content only. Both compounds are prescription medications approved for specific indications. This is not medical advice or a recommendation to use either compound.
Key Reference
- Garvey WT, et al. Tirzepatide versus Semaglutide for Obesity. N Engl J Med. 2025. DOI: 10.1056/NEJMoa2410819
